If you have been reading about GLP-1 receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
This process has also been observed in simulations of transthyretin and implicated as occurring naturally in certain protein families by examination of their dihedral angle conformations in crystal structures. It is suggested that alpha-sheet folds into multi-strand solenoids.
== Epidemiology == Although there is no definitive reporting on its incidence, acrocyanosis shows prevalence in children and young adults than in patients thirty years of age or older. Epidemiological data suggests that cold climate, outdoor occupation, and low body mass index are significant risk factors for developing acrocyanosis. As expected, acrocyanosis would be more prevalent in women than in men due to differences in BMI. However, the incidence rate of acrocyanosis often decreases with increasing age, regardless of regional climate. It completely resolves in many women after menopause implying significant hormonal influences. There is some evidence that many cases of idiopathic acrocyanosis are in some way related to a disorder of estrogen, or aromatase. Around 50% of patients with POTS experience acrocyanosis of their legs while standing still.
== Related heterocycles == Benzimidazole, an analog with a fused benzene ring Dihydroimidazole or imidazoline, an analog where the 4,5-double bond is saturated Pyrrole, an analog with only one nitrogen atom in position 1 Oxazole, an analog with the nitrogen atom in position 1 replaced by oxygen Thiazole, an analog with the nitrogen atom in position 1 replaced by sulfur Pyrazole, an analog with two adjacent nitrogen atoms Triazoles, analogs with three nitrogen atoms
Sources: en.wikipedia.org
==== Tandem models ==== Between 1958 and 1973, HVEC manufactured 55 tandem accelerators in four progressively larger models. Each generation opened new experiments with heavier ions, higher energies, and previously inaccessible nuclear reactions. The EN model became the production workhorse. First installed at Chalk River in 1959, it was the first large accelerator to use pure sulfur hexafluoride as insulating gas, which allowed higher voltages in a smaller tank. Its commercial viability depended on two developments: sufficiently intense negative ion sources (developed at Chalk River and Wisconsin) and HVEC's invention of the inclined-field acceleration tube, which solved the voltage breakdown problem that had plagued earlier long tubes. HVEC built 30 EN units for institutions across seven countries. At Chalk River, researchers used the EN to discover quasi-molecular states—transient configurations where colliding nuclei briefly orbit each other before separating. The FN model ("King") extended terminal voltages to 9 megavolts in its "Super FN" variant. The first went to Los Alamos in October 1963. HVEC sold 17 FN units to laboratories including Rutgers, Florida State, Stanford, and national research institutes in France and Romania. The MP model ("Emperor"), a much larger model commissioned by the Atomic Energy Commission in 1962, employed an "open truss" column structure—beams fabricated from alternating steel and glass plates bonded with epoxy—that supported a substantially larger terminal while maintaining electrical insulation.
== Medical uses == Metoprolol is used for a number of conditions, including angina, acute myocardial infarction, high blood pressure, supraventricular tachycardia, ventricular tachycardia, congestive heart failure, and prevention of migraine headaches. It is an adjunct in the treatment of hyperthyroidism. Both oral and intravenous forms of metoprolol are available for administration. The different salt versions of metoprolol – metoprolol tartrate (short acting) and metoprolol succinate (long acting) – are significantly different from one another and should not be substituted for one another except when used as directed by a medical professional. Off-label uses include supraventricular tachycardia and thyroid storm.
21 February – The Government agreed a more targeted cost-of-living package, along with some universal payments, with €470m to be allocated for social protection measures. 22 February – Róisín Shortall and Catherine Murphy announced that they would stand down as co-leaders of the Social Democrats, with a successor to be appointed "at an early date." On 26 February, Holly Cairns was announced as the next leader of the party. 28 February – Minister for Education Norma Foley reversed a plan for Leaving Certificate candidates to sit Paper 1 of their English and Irish exams at the end of fifth year, after facing strong opposition from a number of organisations, including teacher and student representative bodies.
Silica alumina gel - light yellow, chemically stable, flame-resistant, insoluble except in alkali or hydrofluoric acid. Superficial polarity, thermal stability, performance greater than fine-pored silica gel. Stabilizing silica gel - non-crystalline micro-porous solid powder, nontoxic, flame-resisting, used in brewery of grains for beer to improve taste, clearness, color, and foam and for removal of non-micro-organism impurities.
Sources: en.wikipedia.org
BrO3− + 5 Br− + 6 H+ → 3 Br2 + 3 H2O There were many failed attempts to obtain perbromates and perbromic acid, leading to some rationalisations as to why they should not exist, until 1968 when the anion was first synthesised from the radioactive beta decay of unstable 83SeO42−. Today, perbromates are produced by the oxidation of alkaline bromate solutions by fluorine gas. Excess bromate and fluoride are precipitated as silver bromate and calcium fluoride, and the perbromic acid solution may be purified. The perbromate ion is fairly inert at room temperature but is thermodynamically extremely oxidising, with extremely strong oxidising agents needed to produce it, such as fluorine or xenon difluoride. The Br–O bond in BrO4− is fairly weak, which corresponds to the general reluctance of the 4p elements arsenic, selenium, and bromine to attain their group oxidation state, as they come after the scandide contraction characterised by the poor shielding afforded by the radial-nodeless 3d orbitals.
=== Other === More generally, fluoroquinolones are tolerated, with typical drug side effects being mild to moderate. Common side effects include gastrointestinal effects such as nausea, vomiting, and diarrhea, as well as headache and insomnia. Postmarketing surveillance has revealed a variety of relatively rare but serious adverse effects associated with all members of the fluoroquinolone antibacterial class. Among these, tendon problems and exacerbation of the symptoms of the neurological disorder myasthenia gravis are the subject of "black box" warnings in the United States. A 2018 EU-wide review of fluoroquinolones concluded that they are associated with serious side effects including tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impaired hearing, vision, taste and smell. Tendon damage (especially to Achilles tendon but also other tendons) can occur within 48 hours of starting fluoroquinolone treatment but the damage may be delayed several months after stopping treatment. The overall rate of adverse events in people treated with fluoroquinolones is roughly similar to that seen in people treated with other antibiotic classes. A U.S.
== Literature == Carl-Gerd Dieris: Zur Frage der Luminiszenz von thermooxidativ geschädigten Polycarpolaktam. Eine neue Synthese des Bakterienfarbstoffes Indigoidin und seiner Tetra-N-alkylderivate. 1980. Hans Günter Schlegel: Allgemeine Mikrobiologie. Thieme Verlagsgruppe, Stuttgart 1992, ISBN 978-3-13-444607-4. Reverchon, Sylvie; Rouanet, Carine; Expert, Dominique; Nasser, William (2002-01-02). "Characterization of Indigoidine Biosynthetic Genes in Erwinia chrysanthemi and Role of This Blue Pigment in Pathogenicity". Journal of Bacteriology. 184 (3): 654–665. doi:10.1128/JB.184.3.654-665.2002. PMC 139515. PMID 11790734. Christin Schönfeld: Charakterisierung und biochemische Analyse der Indigoidin Synthease BpsA aus S. lavendulae ATCC 11924. Masterarbeit, Philipps-Universität Marburg 2012. M. Müller, S. Ausländer, D. Ausländer, C. Kemmer, M. Fussenegger: A novel reporter system for bacterial and mammalian cells based on the non-ribosomal peptide indigoidine. Metabolic Engineering 14/2012, S. 325–335 (doi:10.1016/j.ymben.2012.04.002). H. Kobayashi, Y. Nogi, K. Hirokoshi: New violet 3,3'-bipyridyl pigment purified from deep-sea microorganism Shewanella violacea DSS12. In: Extremophiles Nr. 11(2)/2012, S. 245–250. PMID 17102923.
== Awards == 1988 Du Vigneaud Award for Young Investigators in Peptide Research 1989 Protein Society Young Investigator Award 1992 Eli Lilly Award in Biological Chemistry 1993 DuPont Merck Summit Award 1995 Fellow, American Association for the Advancement of Science 1998 Fellow, AAAS 1999 Member, National Academy of Sciences (U.S.A.) 2003 The American Peptide Society Merrifield Award 2008 The American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry 2009 The American Peptide Society Makineni Award 2015 The Stein & Moore Award of the Protein Society 2016 Weizmann Institute Max Perutz Memorial Lecture 2018 The American Chemical Society Cope Scholar Award 2018 The American Chemical Society Murray Goodman Memorial Prize 2020 The Franklin Institute & City Council of Philadelphia John C. Scott Award 2025 ACS Ronald Breslow Award for Achievement in Biomimetic Chemistry
=== Development === Under the code names JNJ-39823277 and TPI-1062, tianeptine was previously under development for the treatment of major depressive disorder in the United States and Belgium. Phase I clinical trials were completed in Belgium and the United States in May and June 2009, respectively. For unclear reasons development of tianeptine was discontinued in both countries in January 2012. In October 2023, Tonix Pharmaceuticals announced that it had discontinued its development of tianeptine as a monotherapy for major depressive disorder after disappointing phase-2 clinical trial results. An ongoing clinical trial, sponsored by the New York Psychiatric Institute, is examining tianeptine's use in treatment-resistant depression. U.S. National Poison Data System data on tianeptine showed a nationwide increase in tianeptine exposure calls and calls related to abuse and misuse during 2014–2017.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the usual choice, with results reported as area percent. Complementary methods such as size-exclusion chromatography and mass spectrometry are needed because a single separation cannot resolve every impurity class. Purity figures are therefore method dependent and should always be read alongside the technique used.